MedTrace Logo

A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer

NCT02402036 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-01-29

Study results available
· View outcomes & findings →

Summary

This is an exploratory biomarker study. Patients with metastatic colorectal cancer will receive regorafenib, which is FDA approved in this setting, on day 1-21 of every consecutive 28 day cycle. Patients will be asked to undergo tumor biopsy at baseline and 2 weeks after starting regorafenib. Peripheral blood samples will be collected at baseline 2 weeks after starting regorafenib, after initiation of cycle 3, and every 4 weeks thereafter.

Conditions

Interventions

DRUG

Regorafenib

Regorafenib orally for 21 days every 28 day cycle

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Georgetown University

    lead OTHER

Principal Investigators

  • John Marshall, MD · Georgetown University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02402036 on ClinicalTrials.gov